Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/35811
Title: MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
Authors: 
Keywords: 
Mesh: 
Issue Date: 17-Aug-2018
Citation: J. Exp. Clin. Cancer Res..2018 Aug;(37)1:195
Abstract: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression.
PMID: 30119639
URI: https://hdl.handle.net/20.500.12530/35811
Rights: openAccess
Appears in Collections:Hospitales > H. U. 12 de Octubre > Artículos
Fundaciones e Institutos de Investigación > IIS H. U. 12 de Octubre > Artículos

Files in This Item:
File Description SizeFormat 
PMC6098621.pdf3.05 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.